CELU: Celularity Corp Average Forecast Price
Celularity Inc. (CELU) generates revenue through the development of placenta-derived cell products for tissue regeneration and oncology therapy, which is reflected in the market dynamics at the 5.99 level. Growth depends on FDA approvals and biomedical breakthroughs; however, pricing power is constrained by US insurance reimbursement limits, which restricts the ability to increase the cost of innovative drugs.
Analytical breakdowns for Celularity Inc. (CELU)
- market price and analyst price targets:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity Celularity Inc.|CELU - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital celularity.com|CELU - Company Aggregate Debts|Debts to Book Capitalization Celularity Corp|CELU - Company Long-Term Debt|Company Short-Term Loans and Borrowings Celularity|Quick Liquidity Indicator celularity.com
- financial results and valuation multiples details:
CELU - Net Profit|Projected Future Earnings Celularity Inc.|CELU - Price to Earnings Ratio|Future Price to Earnings Multiple celularity.com|CELU - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Celularity Corp|CELU - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Celularity|CELU - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months celularity.com|CELU - Net earnings per share growth this year|Earnings growth forecast for next year Celularity Inc.
General company analysis:CELU Celularity Inc
Fund managers' interest in the operating model of Celularity Inc. (CELU) is driven by patents in regenerative medicine, rendering the current consensus target price a key indicator of the business's fair value. This metric aggregates expert forecasts to determine the direction of price action, allowing investors to manage capital freeze risks and confirm the stability of the issuer's market positions.
Competitors of Celularity Inc.
Consensus Target argenx.com ARGX|Analyst Consensus Forecast BNTX (BioNTech)|Abivax SA (ABVX) - Average Forecast Price|ADMA - Price Target Chart|PTGX: Price Target Chart|IMVT (Immunovant, Inc.) - Consensus Target|kiniksa.com (KNSA) - Analyst Consensus Forecast|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|Aclaris Therapeutics, Inc (ACRS) - Consensus Target|KYTX: Analyst Consensus Forecast|Average Forecast Price tizianalifesciences.com (TLSA)|Price Target Chart Cabaletta Bio|Price Target Chart VTYX|Consensus Target THTX (Theratechnologies Inc)|Analyst Consensus Forecast Avalo Therapeutics Inc (AVTX)|Price Target Chart Eledon Pharmaceuticals ELDN|agenusbio.com - Price Target Chart|Climb Bio - Analyst Consensus Forecast|ZURA - Analyst Consensus Forecast|aTyr (ATYR) - Price Target Chart|Adagene Inc. - Fair Value Consensus|IMA (ImageneBio) - Analyst Consensus Forecast|Shattuck Therapeutics (STTK) - Analyst Median Target|Consensus Target EQ (Equillium, Inc.)|Analyst Forecast Prices CNTB|Immunic - Consensus Target|Atara Biotherapeutics, Inc. (ATRA) - Average Forecast Price|IFRX: Consensus Target|Fair Value Consensus XFOR (x4pharma.com)|ACET: Analyst Consensus Forecast|INMB - Analyst Median Target|Price Target Chart Barinthus Bio|Broker Consensus Forecast KZR (Kezar Life Sciences Inc)|Analyst Consensus Forecast SABS|Consensus Target akaritx.com AKTX|Enlivex Therapeutics Ltd. - Consensus Target|Analyst Median Target Q32 Bio Inc (QTTB)|GeoVax Labs Inc - Analyst Consensus Forecast|Edesa Biotech Corp (EDSA) - Consensus Target|IBIO: Analyst Consensus Forecast|Average Forecast Price Carisma Therapeutics Inc. (CARM)|Price Target Chart XTL Biopharmaceuticals Ltd.|Price Target Chart BOLT|Consensus Target HCWB (HCW Biologics Inc.)|Analyst Consensus Forecast aptevotherapeutics.com (APVO)|Price Target Chart AIM ImmunoTech AIM|ADTX (Aditxt Inc.) - Forecast Levels Chart|GRI Bio - Analyst Consensus Forecast|Fair Value Consensus XRTX (XORTX Therapeutics Inc)|HIND: Analyst Consensus Forecast|Revelation Biosciences Corp (REVB) - Analyst Consensus Forecast|Price Target Chart Indaptus Therapeutics|SCNI: Fair Value Consensus|Price Target Chart CalciMedica, Inc. (CALI)|Consensus Target affimed.com AFMD|Analyst Consensus Forecast ALLK (Allakos)|Analyst Consensus Forecast HOOKIPA Pharma, Inc. HOOK|IGMS: Consensus Target|Fair Value Consensus ITOS (iteostherapeutics.com)|OCEA: Analyst Consensus Forecast|TCBP - Analyst Median Target|Price Target Chart Third Harmonic Bio, Inc
